@MidwesternDoc Another company, AVIcure, completed Phase II and Phase III trials for UVBI use in hepatitis C—again showing benefit and safety. But the moment an expensive antiviral drug hit the market, investor interest evaporated! How strange. Except it’s not. A non-patentable therapy, no